Tissue Therapies patent accepted in Australia
Tuesday, 31 May, 2005
The core patent for Tissue Therapies' (ASX:TIS) VitroGro growth factor complex, used to accelerate wound healing, has been accepted in Australia.
The acceptance follows the granting of the core VitroGro patent in New Zealand in March, the first jurisdiction to do so.
Tissue Therapies has worldwide exclusive rights to commercialise VitroGro under an IP Agreement with the Queensland University of Technology, and will also seek core patents for VitroGro in other jurisdictions such as the USA, Canada, Europe, South Korea, China and Japan.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...
